A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects With Spinocerebellar Ataxia
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Trigriluzole (Primary)
- Indications Spinocerebellar ataxias
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceutical Holding Company
- 07 Aug 2017 According to a Biohaven Pharmaceutical Holding Company media release, dosing of all patients has been commenced in this trial. Top-line results are now expected in the fourth quarter of 2017.
- 12 Jul 2017 The results of this trial will also support regulatory filings in Europe and Japan according to a Portage Biotech media release.
- 30 May 2017 According to a Biohaven Pharmaceutical media release, the company expects to submit an NDA to the FDA in early 2018 based on the results of this trial.